DOI: 10.11648/j.ijgg.20261403.13 ISSN: 2376-7359

In-Silico Multi-Omics Analysis of the Transcriptomic and Immuno-Genomic Significance of Gastric Cancer Hallmark Genes HMMR, CDH1, NPM1 and HDAC5 as Biomarkers

Srishti Dutta, Debaleena Samanta, Malavika Bhattacharya
Show PDF Cite
Important regulators of tumor growth, metastasis, and cellular regulation include Hyaluronan-mediated motility receptor (HMMR), Cadherin-1 (CDH1), Nucleoplasmin-1 (NPM1), and Histone deacetylase-5 (HDAC5). This study used bioinformatics technologies to examine their interrelationships and differential expression in gastric cancer. GEO2R was implemented to analyze DEGs from publicly available gastric cancer datasets. Venn analysis was then used to identify common DEGs, and heat-map visualization was used to evaluate expression patterns. Gastric cancer transcriptomic data were retrieved from the NCBI GEO database and analysed using GEO2R and Limma to identify DEGs. Visualization included volcano, box, and UMAP plots. Overlapping genes were assessed via BioVenn. Functional enrichment used GSEA, while immune infiltration was analysed through TIMER. Gene datasets for HMMR, CDH1, NPM1, and HDAC5 were retrieved from NCBI GEO and analysed for differential expression, revealing variable up- and downregulation across samples. Venn analysis showed minimal gene overlap. Enrichment analysis indicated significant expression patterns, particularly for HMMR and NPM1. Immune correlation revealed weak-to-moderate associations with CD8+ T cells. Mutation frequencies varied, with CDH1 highest (35%). sCNA and RNA-seq analyses demonstrated statistically significant alterations, supporting their potential roles in gastric cancer progression. Overall, the integrated bioinformatic approach showed different expression profiles of HMMR, CDH1, NPM1, and HDAC5 in gastric cancer. While altered expression of HMMR and HDAC5 highlights their potential contribution to cancer-related signaling and epigenetic regulation, NPM1 overexpression and CDH1 loss indicate opposing roles in tumor progression.

More from our Archive